Report Phase 2 clinical trial results of ADX-629 in multiple systemic indications

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced: 28 Oct 2021
Due: 31 Mar 2022
Checked: 2 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“Phase 2 Clinical Trial Results of ADX-629 in Multiple Systemic Indications Expected in the Fourth Quarter of 2021 or the First Quarter of 2022”

SourceAldeyra Therapeutics, Inc. Form 8-K press release, 2021-10-28
FilingSEC filing index
Deadline as statedin the Fourth Quarter of 2021 or the First Quarter of 2022
Deadline used31 Mar 2022, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-ALDX-003448
Cite as https://keptindex.org/c/KI-C-2021-ALDX-003448/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company did not report the Phase 2 results for ADX-629 by the Q1 2022 deadline, later stating in 2023 that these results were announced throughout 2022.

A
Aldeyra Therapeutics, Inc. 10-K filed 2023-03-09 Regulatory filing · published 9 Mar 2023 · retrieved 2 Oct 2026 · kept permanently by the SEC · fingerprint ebbebd71f16e
“In 2022, we announced results from Phase 2a clinical trials of ADX‑629 in patients with psoriasis, atopic asthma, COVID-19, or alcohol intoxication” ✓ confirmed on the page

Market reaction: the shares moved -1.4% against the S&P 500 over the three sessions around the disclosure (8 Mar 2023 to 13 Mar 2023). What this measures

Checked 2 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +1371 days
2 versions

Version 1 · original · stated 28 Oct 2021

Deadline 31 Mar 2022 (“in the Fourth Quarter of 2021 or the First Quarter of 2022”) · wording expected
Version 2 · stated 3 Apr 2025

Deadline 31 Dec 2025 (“2025”) · wording expected

“Moderate Alcohol-Associated Hepatitis (ADX-629) ‡ Open-label Phase 2 clinical trial top-line results expected in 2025”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Phase 2 clinical trial results of ADX-629
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: Medium

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: disagreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and read it as “no_evidence”, so a person decides.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.